Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-42344 Influenza Challenge Study
NCT06160531Phase 2Completed
- Sponsor
- Cocrystal Pharma
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CC-42344 in Influenza A (IAV) (3 arms), sponsored by Cocrystal Pharma. Primary endpoint: Area under the influenza viral load-time curve. Started Nov 2023; status: completed.
02
Drugs
CC-42344
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT06160531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160531.